S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
HUM · Humana Inc.
NEW YORK STOCK EXCHANGE, INC. - BOATS Real Time Price • USD
$424.64
-3.50
(-0.82%)
● At close: October 21 at 4:00:00 PM EDT
$425.42
+0.00
(+0.00%)
Overnight:
10:26:23 PM EDT
DAY'S RANGE
$424.64
$423.94
$433.46
52-WEEK RANGE
$424.64
$163.11
$456.50
What's happening
- HUM is down 0.82% today, trading at $424.64. — Live quote
- Volume today (96,810) is well below its 3-month average of 1,382,920. (Finnhub fundamentals)
- Reports earnings on 2026-11-06 (before market open), 15 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $7.61 actual vs. $7.29 estimated (+4.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 8
Hold 15
Sell 1
Strong sell 0
Aggregate ratings for 2026-10-01 (32 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
HUM
+66.10%
vs S&P 500
+52.73%
1-YEAR RETURN
HUM
+44.11%
vs S&P 500
+28.95%
6-MONTH RETURN
HUM
+107.38%
3-MONTH RETURN
HUM
+7.00%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$7.61
Est. $7.29
BEAT +4.3%
2026-04-26 (Q1 2026)
$10.31
Est. $10.29
BEAT +0.2%
2026-01-26 (Q4 2025)
$-3.96
Est. $-4.05
BEAT +2.1%
2025-10-26 (Q3 2025)
$3.24
Est. $2.85
BEAT +13.8%
Valuation Measures & Ratios
Enterprise Value4$58.60B
Forward P/E525.49
PEG Ratio61.70
Price / Sales (TTM1)0.35
Price / Book72.48
EV4 / Revenue0.40
EV4 / EBITDA17.77
Profit Margin0.88%
Operating Margin1.81%
Return on Equity (ROE8)6.92%
Return on Assets (ROA9)2.42%
Avg Volume (3M)1,382,920
Quarterly history (5 periods)
| Measure | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 |
|---|---|---|---|---|---|
| Market cap | $20.89B | $30.99B | $29.14B | $31.37B | — |
| P/E | 6.59 | 12.58 | 9.88 | 9.98 | — |
| Price/Sales | 0.15 | 0.24 | 0.24 | 0.26 | — |
| Price/Book | 1.12 | 1.67 | 1.60 | 1.77 | — |
| EV/Revenue | 0.21 | 0.30 | 0.31 | 0.33 | — |
| ROE | 17.06% | 13.30% | 16.17% | 17.71% | — |
| ROA | 5.73% | 4.96% | 5.85% | 6.17% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,789,982
Change from Prior Settlement-2.01%
% of Float—
Days to Cover (Short Ratio)2.24
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 26.2% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +44.1%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is 0.9%. Finnhub fundamentals ↗
- Trailing P/E is 40.1, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on HUM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Sep '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.65B | $32.65B | $32.39B | $32.11B | $29.40B | $29.54B | $29.61B | $26.42B |
| Operating income | $1.75B | $400.0M | $1.10B | $2.01B | $728.0M | $1.14B | $1.24B | $1.21B |
| Net income | $1.19B | $195.0M | $545.0M | $1.24B | $480.0M | $679.0M | $741.0M | $832.0M |
| EPS (diluted) | $9.83 | $1.62 | $4.51 | $10.30 | $3.98 | $5.62 | $6.11 | $6.71 |
| EPS (basic) | $9.85 | $1.62 | $4.52 | $10.31 | $3.99 | $5.63 | $6.13 | $6.74 |
| Operating margin | $4 | $1 | $3 | $6 | $2 | $4 | $4 | $5 |
| Net margin | $3 | $1 | $2 | $4 | $2 | $2 | $3 | $3 |
Balance sheet
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $55.28B | $48.91B | $49.72B | $50.36B | $50.93B | $46.48B | $50.01B | $50.09B |
| Total liabilities | $36.63B | $31.17B | $31.14B | $32.06B | $33.11B | $30.03B | $32.38B | $33.37B |
| Stockholders' equity | $18.58B | $17.66B | $18.52B | $18.23B | $17.75B | $16.38B | $17.57B | $16.67B |
| Total current assets | $38.08B | $32.73B | $32.75B | $33.62B | $34.42B | $29.82B | $32.93B | $32.86B |
| Total current liabilities | $21.51B | $16.35B | $16.18B | $17.22B | $18.04B | $16.94B | $18.73B | $19.79B |
| Cash & equivalents | $4.95B | $4.20B | $5.39B | $4.04B | $4.25B | $2.22B | $5.12B | $5.50B |
| Marketable securities (current) | $17.01B | $15.70B | $16.74B | $17.67B | $17.89B | $18.21B | $19.03B | $17.42B |
| Accounts receivable | $5.22B | $3.27B | $2.68B | $4.50B | $4.46B | $2.70B | $2.14B | $4.09B |
| Other current assets | $10.90B | $9.56B | $7.94B | $7.40B | $7.83B | $6.68B | $6.63B | $5.84B |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $2.17B | $2.23B | $2.27B | $2.36B | $2.43B | $2.53B | $2.69B | $2.82B |
| Goodwill | $10.49B | $9.69B | $9.62B | $9.63B | $9.63B | $9.63B | $9.59B | $9.57B |
| Intangible assets | $1.19B | $1.13B | $1.23B | $1.38B | $1.43B | $1.44B | $1.65B | $1.66B |
| Other non-current assets | $3.28B | $3.13B | $4.02B | $3.69B | $3.38B | $3.38B | $3.67B | $3.72B |
| Deferred revenue (current) | $269.0M | $356.0M | $265.0M | $274.0M | $265.0M | $260.0M | $195.0M | $313.0M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | $12.27B | $12.37B | $12.61B | $12.59B | $12.73B | $11.14B | $11.89B | $11.75B |
| Other non-current liabilities | $2.85B | $2.46B | $2.35B | $2.26B | $2.34B | $1.95B | $1.77B | $1.83B |
| Common stock & paid-in capital | $33.0M | $33.0M | $33.0M | $33.0M | $33.0M | $33.0M | $33.0M | $33.0M |
| Retained earnings | $30.15B | $29.07B | $29.98B | $29.89B | $29.45B | $28.32B | $29.12B | $28.75B |
| Accumulated other comprehensive income (loss) | -$731.0M | -$633.0M | -$666.0M | -$783.0M | -$868.0M | -$1.07B | -$653.0M | -$1.12B |
Cash flow
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.25B | -$1.65B | $971.0M | $1.27B | $331.0M | -$528.0M | $1.86B | $1.21B |
| Investing cash flow | -$2.55B | $632.0M | $980.0M | $347.0M | $314.0M | -$63.0M | -$1.47B | -$1.00B |
| Financing cash flow | $2.05B | -$168.0M | -$603.0M | -$1.83B | $1.38B | -$2.30B | -$770.0M | -$620.0M |
| Free cash flow | $1.13B | -$1.85B | $836.0M | $1.16B | $236.0M | -$682.0M | $1.73B | $1.10B |
| Capital expenditures | $121.0M | $202.0M | $135.0M | $114.0M | $95.0M | $154.0M | $130.0M | $114.0M |
| Share-based compensation | $51.0M | $48.0M | $83.0M | $61.0M | $49.0M | $54.0M | $53.0M | $55.0M |
| Deferred income taxes | — | $75.0M | — | — | — | -$192.0M | — | — |
| Purchases of investments | $2.89B | $1.24B | $3.26B | $1.11B | $827.0M | $2.14B | $3.16B | $1.62B |
| Sales/maturities of investments | $395.0M | $1.44B | $3.82B | $721.0M | $522.0M | $1.62B | $1.26B | $108.0M |
| Other investing activities | — | $0 | — | — | — | $50.0M | — | — |
| Dividends paid | $107.0M | $109.0M | $107.0M | $106.0M | $108.0M | $108.0M | $107.0M | $107.0M |
| Share repurchases | $107.0M | $42.0M | $0 | $100.0M | $9.0M | $49.0M | $2.0M | $49.0M |
| Debt issued | $990.0M | — | — | — | $1.48B | — | — | — |
| Debt repaid | $10.0M | — | — | — | $0 | — | — | — |
| Other financing activities | -$18.0M | -$5.0M | -$14.0M | -$50.0M | -$12.0M | -$8.0M | -$7.0M | -$64.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $129.66B | $117.76B | $106.37B | $92.87B | $83.06B |
| Operating income | $2.70B | $2.56B | $4.01B | $3.80B | $3.15B |
| Net income | $1.19B | $1.21B | $2.49B | $2.81B | $2.93B |
| EPS (diluted) | $9.84 | $9.98 | $20.00 | $22.08 | $22.67 |
| EPS (basic) | $9.87 | $10.01 | $20.09 | $22.20 | $22.79 |
| Operating margin | $2 | $2 | $4 | $4 | $4 |
| Net margin | $1 | $1 | $2 | $3 | $4 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $48.91B | $46.48B | $47.06B | $43.05B | $44.36B |
| Total liabilities | $31.17B | $30.03B | $30.75B | $27.68B | $28.25B |
| Stockholders' equity | $17.66B | $16.38B | $16.26B | $15.31B | $16.08B |
| Total current assets | $32.73B | $29.82B | $29.99B | $26.18B | $24.89B |
| Total current liabilities | $16.35B | $16.94B | $18.87B | $17.18B | $15.33B |
| Cash & equivalents | $4.20B | $2.22B | $4.69B | $5.06B | $3.39B |
| Marketable securities (current) | $15.70B | $18.21B | $16.63B | $13.88B | $13.19B |
| Accounts receivable | $3.27B | $2.70B | $2.04B | $1.67B | $1.81B |
| Other current assets | $9.56B | $6.68B | $6.63B | $5.57B | $6.49B |
| Property, plant & equipment | $2.23B | $2.53B | $3.03B | $3.22B | $3.07B |
| Goodwill | $9.69B | $9.63B | $9.55B | $9.14B | $11.09B |
| Intangible assets | $1.13B | $1.44B | $1.69B | $1.76B | $2.64B |
| Other non-current assets | $3.13B | $3.38B | $3.38B | $3.38B | $4.38B |
| Deferred revenue (current) | $356.0M | $260.0M | $266.0M | $286.0M | $254.0M |
| Short-term debt | — | — | — | — | — |
| Long-term debt | $12.37B | $11.14B | $10.21B | $9.03B | $10.54B |
| Other non-current liabilities | $2.46B | $1.95B | $1.66B | $1.47B | $2.38B |
| Common stock & paid-in capital | $33.0M | $33.0M | $33.0M | $33.0M | $33.0M |
| Retained earnings | $29.07B | $28.32B | $27.54B | $25.49B | $23.09B |
| Accumulated other comprehensive income (loss) | -$633.0M | -$1.07B | -$999.0M | -$1.30B | $42.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $921.0M | $2.97B | $3.98B | $4.59B | $2.26B |
| Investing cash flow | $2.27B | -$2.95B | -$3.49B | -$1.01B | -$6.56B |
| Financing cash flow | -$1.22B | -$2.49B | -$856.0M | -$1.91B | $3.02B |
| Free cash flow | $375.0M | $2.39B | $2.98B | $3.45B | $920.0M |
| Capital expenditures | $546.0M | $575.0M | $1.00B | $1.14B | $1.34B |
| Share-based compensation | $241.0M | $207.0M | $175.0M | $216.0M | $180.0M |
| Deferred income taxes | $75.0M | -$192.0M | -$164.0M | -$100.0M | $15.0M |
| Purchases of investments | $6.44B | $8.19B | $7.55B | $6.05B | $7.20B |
| Sales/maturities of investments | $6.51B | $3.38B | $3.79B | $2.43B | $3.55B |
| Other investing activities | $0 | $50.0M | $0 | $0 | — |
| Dividends paid | $430.0M | $431.0M | $431.0M | $392.0M | $354.0M |
| Share repurchases | $151.0M | $817.0M | $1.57B | $2.10B | $79.0M |
| Debt repaid | — | — | — | — | — |
| Other financing activities | -$81.0M | -$108.0M | -$151.0M | $9.0M | $21.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding HUM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers74.0%
Shares Outstanding120,080,308
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| DODGE & COX | 10,940,380 | $4.35B | 9.11% | -3.9% | 2026-08-13 |
| BlackRock, Inc. | 10,417,803 | $4.14B | 8.68% | +2.1% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,843,620 | $3.12B | 6.53% | +0.1% | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,818,956 | $2.31B | 4.85% | +0.2% | 2026-06-30 |
| State Street Corp | 5,457,072 | $2.17B | 4.54% | +0.1% | 2026-08-07 |
| PZENA INVESTMENT MANAGEMENT LLC | 4,403,136 | $1.75B | 3.67% | -19.5% | 2026-08-07 |
| EAGLE CAPITAL MANAGEMENT LLC | 3,846,762 | $1.53B | 3.20% | +29.6% | 2026-08-14 |
| Sessa Capital IM, L.P. | 3,727,740 | $1.48B | 3.10% | +0.0% | 2026-08-14 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 3,578,245 | $1.66B | 2.98% | -20.2% | 2026-08-03 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,369,757 | $1.34B | 2.81% | +1.3% | 2026-08-12 |
| Jpmorgan Chase & Co | 3,234,637 | $1.26B | 2.69% | +6.6% | 2026-08-12 |
| FMR LLC | 2,913,763 | $1.16B | 2.43% | +2.8% | 2026-08-13 |
| Capital International Investors | 2,392,826 | $950.5M | 1.99% | +20.5% | 2026-08-07 |
| Goldman Sachs Group Inc | 2,299,889 | $913.6M | 1.92% | +20.7% | 2026-08-14 |
| NAYA CAPITAL MANAGEMENT UK LTD | 1,833,763 | $728.4M | 1.53% | +10.1% | 2026-08-14 |
| NORGES BANK | 1,748,414 | $694.5M | 1.46% | +0.0% | 2026-08-12 |
| Invesco Ltd. | 1,478,788 | $587.4M | 1.23% | -38.0% | 2026-08-13 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,370,831 | $544.5M | 1.14% | +6.5% | 2026-08-14 |
| Morgan Stanley | 1,349,066 | $535.9M | 1.12% | -6.8% | 2026-08-11 |
| DIMENSIONAL FUND ADVISORS LP | 1,122,669 | $445.8M | 0.93% | -7.4% | 2026-08-11 |
| Capital Research Global Investors | 1,116,990 | $443.5M | 0.93% | +1.6% | 2026-08-07 |
| Northern Trust Corp | 1,115,198 | $443.0M | 0.93% | -2.2% | 2026-08-12 |
| Slate Path Capital LP | 1,079,930 | $429.0M | 0.90% | +134.9% | 2026-08-14 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,072,296 | $425.9M | 0.89% | -2.0% | 2026-08-13 |
| Capital World Investors | 1,022,425 | $406.1M | 0.85% | +981.9% | 2026-08-07 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-12 to 2026-09-01
Recent transactions
- Most recent: Nundy Shantanu (Chief Medical Officer) — Grant / award of 2,549 shares on 2026-09-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Nundy Shantanu | Chief Medical Officer | Grant / award | 2026-09-01 | 2,549 |
| Smith Paul John | Director | Grant / award | 2026-08-01 | 544 |
| Crawford Frederick John | Director | Grant / award | 2026-08-01 | 544 |
| Mellet Celeste | Chief Financial Officer | Grant / award | 2026-05-01 | 15,387 |
| Mehta Japan | Chief Information Officer | Grant / award | 2026-05-01 | 9,448 |
| Dintenfass David | President, Enterprise Growth | Grant / award | 2026-05-01 | 11,273 |
| Rechtin James A. | President & CEO | Grant / award | 2026-05-01 | 35,633 |
| O'Hara Michelle A. | Chief Human Resources Officer | Grant / award | 2026-05-01 | 10,485 |
| Field Robert Stuart | Director | Grant / award | 2026-05-01 | 852 |
| Ventura Joseph C | Chief Legal Officer | Grant / award | 2026-05-01 | 10,318 |
| Shetty Sanjay K | President, CenterWell | Grant / award | 2026-05-01 | 9,945 |
| Martin Aaron | President, Medicare Advantage | Grant / award | 2026-05-01 | 8,206 |
| Renaudin George II | President, Insurance | Option exercise | 2026-02-24 | 1,035 |
| Felter John-Paul W. | SVP, Chief Accting Off & Cont. | Option exercise | 2026-02-24 | 165 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Nundy Shantanu | Chief Medical Officer | Grant / award | 2,549 | $0.00 |
| 2026-08-01 | Smith Paul John | Director | Grant / award | 544 | $0.00 |
| 2026-08-01 | Crawford Frederick John | Director | Grant / award | 544 | $0.00 |
| 2026-05-01 | Mellet Celeste | Chief Financial Officer | Grant / award | 15,387 | $0.00 |
| 2026-05-01 | Mehta Japan | Chief Information Officer | Grant / award | 9,448 | $0.00 |
| 2026-05-01 | Dintenfass David | President, Enterprise Growth | Grant / award | 11,273 | $0.00 |
| 2026-05-01 | Rechtin James A. | President & CEO | Grant / award | 35,633 | $0.00 |
| 2026-05-01 | O'Hara Michelle A. | Chief Human Resources Officer | Grant / award | 10,485 | $0.00 |
| 2026-05-01 | Field Robert Stuart | Director | Grant / award | 852 | $0.00 |
| 2026-05-01 | Ventura Joseph C | Chief Legal Officer | Grant / award | 10,318 | $0.00 |
| 2026-05-01 | Shetty Sanjay K | President, CenterWell | Grant / award | 9,945 | $0.00 |
| 2026-05-01 | Martin Aaron | President, Medicare Advantage | Grant / award | 8,206 | $0.00 |
| 2026-04-01 | Shetty Sanjay K | President, CenterWell | Option exercise | 887 | $0.00 |
| 2026-04-01 | Shetty Sanjay K | President, CenterWell | Tax withholding | 401 | $175.44 |
| 2026-02-24 | Ventura Joseph C | Chief Legal Officer | Option exercise | 1,035 | $0.00 |
| 2026-02-24 | Ventura Joseph C | Chief Legal Officer | Tax withholding | 478 | $177.07 |
| 2026-02-24 | Renaudin George II | President, Insurance | Option exercise | 1,035 | $0.00 |
| 2026-02-24 | Renaudin George II | President, Insurance | Tax withholding | 419 | $177.07 |
| 2026-02-24 | Felter John-Paul W. | SVP, Chief Accting Off & Cont. | Option exercise | 165 | $0.00 |
| 2026-02-24 | Felter John-Paul W. | SVP, Chief Accting Off & Cont. | Tax withholding | 84 | $177.07 |
| 2026-02-23 | Felter John-Paul W. | SVP, Chief Accting Off & Cont. | Grant / award | 5,669 | $0.00 |
| 2026-02-23 | Shetty Sanjay K | President, CenterWell | Open market purchase | 810 | $185.21 |
| 2026-02-21 | Dintenfass David | President, Enterprise Growth | Option exercise | 3,858 | $0.00 |
| 2026-02-21 | Dintenfass David | President, Enterprise Growth | Tax withholding | 1,182 | $189.66 |
| 2026-02-13 | Mehta Japan | Chief Information Officer | Option exercise | 1,682 | $0.00 |
| 2026-02-13 | Mehta Japan | Chief Information Officer | Tax withholding | 430 | $181.46 |
| 2026-02-13 | Mellet Celeste | Chief Financial Officer | Option exercise | 7,763 | $0.00 |
| 2026-02-13 | Mellet Celeste | Chief Financial Officer | Tax withholding | 4,204 | $181.46 |
| 2026-02-12 | Martin Aaron | President, Medicare Advantage | Grant / award | 17,031 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:20 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 8-K | 2026-10-13 | View on SEC.gov → |
| 2026-10-09 | 8-K | 2026-10-09 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-01 | 8-K | 2026-09-01 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-01 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-01 | View on SEC.gov → |
| 2026-07-29 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-01 | 8-K | 2026-06-01 | View on SEC.gov → |
Recent news
Headlines about HUM (Humana Inc.). Links open the publisher — we don’t host full articles.
-
What Healthcare Services Group (HCSG) Said on Its Q3 Earnings Call
Yahoo · 2026-10-21 -
SpaceX earnings roundup, Meta earnings preview, and tech trade fears
Yahoo · 2026-10-21 -
What Could Stop CVS Health Stock Over The Next Six Months?
Yahoo · 2026-10-21 -
Humana Gains From Premium Growth Despite Rising Benefit Costs
Yahoo · 2026-10-21 -
How Clinic JV Funding At Humana (HUM) Has Changed Its Investment Story
Yahoo · 2026-10-21 -
Dow Jones Futures: SpaceX, Supermicro Revive AI Stocks; Tesla, Meta On Deck
Yahoo · 2026-10-21 -
Humana (HUM) Recasts CenterWell Clinics With New Joint Venture And Fresh Capital
Yahoo · 2026-10-21 -
HUM Oct 2026 397.500 call (HUM261023C00397500) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21
No headlines in this category right now — try “All”.